U.S. Markets open in 3 hrs 3 mins

Weekly CFO Buys Highlight

According to GuruFocus insider data, the recent chief financial officer buys were VBI Vaccines Inc. (NASDAQ:VBIV), Cidara Therapeutics Inc. (NASDAQ:CDTX) and Ocugen Inc. (NASDAQ:OCGN).

VBI Vaccines CFO bought 12,000 shares

CFO and Head of Business Development Christopher McNulty bought 12,000 shares for 48 cents per share on Oct. 1. VBI Vaccines has a market cap of $94.102 million and its shares were traded around 53 cents. The company has a price-sales ratio of 10.01. Over the past five years, the company had an annual average earnings growth of 8.90%.


VBI Vaccines announced its second-quarter results with revenue of $640,000 and a gross loss of $1.71 million, while the net loss was $13.17 million. 2018 total revenue was $3.36 million, a 288% increase from 2017. The gross loss was $1.15 million, a 73% increase from the year prior. The net loss was $63.60 million.

CEO and President Jeff Baxter bought 150,000 shares for 50 cents per share on Sept. 30. Chief Business Officer Nell Beattie bought 10,000 shares for 48 cents per share on Oct 1.

Cidara Therapeutics CFO bought 30,000 shares

CFO James E. Levine bought 30,000 shares for $1.91 per share on Sept. 24. Since then, the stock has gained 1.05%. Cidara Therapeutics has a market cap of $60.890 million and its shares were traded around $1.93.

President and CEO Jeffrey Stein bought 52,500 shares for $1.91 per share on Sept. 24. Since then, the share price has increased by 1.05%. Chief Operating Officer Paul Daruwala sold 3,295 shares for $1.88 per share on Oct. 2. Since then, the stock price has increased by 2.66%. Chief Business Officer Neil Abdollahian sold 7,284 shares for $1.98 per share on Oct. 1. Since then, the stock has declined 2.53%.

Ocugen CFO bought 5,000 shares

CFO Sanjay Subramanian bought 5,000 shares for $1.88 per share on Oct. 2. Since then, the stock has risen 2.66%. Ocugen has a market cap of $3.043 million and its shares were traded around $1.93. Over the past five years, Ocugen had an annual average earnings growth of 29.40%.

Director Junge Zhang bought 31,078 shares for $3.09 per share on Sept. 30. Since then, the stock price has tumbled 37.54%.

Disclosure: None.

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.